Hospital Infection Therapeutics Market: Rising Number of Pipeline Drug Molecules to Boost Market Valuation to US$3.62 billion by 2020

The Global hospital infection therapeutics market to grow at a CAGR of 3.1% during the period from 2014 to 2020. The overall market was worth US$3.06 billion in 2013 and it is projected to reach a valuation of US$3.62 billion by 2020.Hospital-acquired infections are caused by bacterial, fungal, and viral pathogens. The report points out that the high prevalence of the various hospital infections is driving the demand for anti-infective drugs. Also, the presence of neonatal population in hospitals that are highly susceptible to infections is boosting the market for hospital infection therapeutics. 

 

However, the report cites that the increasing number of multi-drug resistant bacterial strains is making the antibacterial drugs obsolete. In addition, the lack of skilled nursing staffs in developing and underdeveloped economies is increasing the prevalence of hospital-acquired infections. The global hospital infection therapeutics market has a huge potential to grow with the increasing number of pipeline drug molecules for specific treatment of hospital-acquired infections. The report segments the global hospital infection therapeutics market on the basis of the drug type such as antifungal drugs, antibacterial drugs, and antiviral drugs. Also, the report analyses the pipeline drugs for hospital infections such as Surotomycin, Oritavancin, Eravacycline, Dalvance, Plazomicin, Tedizolid, MK-3415A, Delafloxacin, CAZ AVI, Amikacin Inhale, and Ceftolozane. Depending on the major types of hospital-acquired infections, the report segments the global hospital infection therapeutics market into urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, hospital-acquired pneumonia, and other hospital infections. Hospital-acquired pneumonia has been the key disease in the global hospital infection therapeutics market and accounted for more than 20% share in the market in 2013. It was closely followed by surgical site infections. In the past few years, urinary tract infections have been growing at a rapid rate. 

The report studies the global hospital infection therapeutics market in four key regions: Europe, North America, Asia Pacific, and Rest of the World. In terms of revenue, North America dominates the overall market, closely followed by Europe. The dominance of these two regions in the global hospital infection therapeutics market can be attributed to the high demand for advanced drugs and increased healthcare awareness. In the near future, Asia Pacific will display the fastest growth in the hospital infection therapeutics market.The report describes the vendor landscape of the global hospital infection therapeutics market and profiles some of the key players such as Bayer AG, GlaxoSmithKline, Johnson & Johnson Services, Pfizer, Sanofi, and Merck & Co. Inc. 

 

Browse the full Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report athttp://www.transparencymarketresearch.com/hospital-infection-therapeutics.html

 

The research study has been segmented as below: